We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Forxiga (dapagliflozin) 5 mg no longer authorised for treatment of type 1 diabetes

Since this module was created, effective 25th October 2021 dapagliflozin 5 mg is no longer authorised for the treatment of patients with type 1 diabetes and should no longer be used in this population. This is based on AstraZeneca’s decision to remove the type 1 diabetes indication for dapagliflozin 5 mg.

The removal of the type 1 diabetes indication is not due to any safety concern for dapagliflozin in any indication, including type 1 diabetes.
Play the video to watch Professor Thomas Danne discussing approvals of the new treatment options
So, two of these drugs have been submitted for regulatory approval and the CHMP (Committee for Medicinal Products for Human Use) of the European Medicines Agency has recommended both sotagliflozin and dapagliflozin to be approved for type 1 diabetes. And this was not an easy decision because, although there are these potential benefits to this group, there are also potential risks – in particular genital mycoses. Well, this could be manageable, but there is a much higher risk of DKA (diabetic ketoacidosis) which is, of course, a serious acute complication of type 1 diabetes. And in order to indicate that this adjunct therapy is not for everyone, the CHMP recommended that these drugs only be used in patients with a BMI above 27, because maybe these patients have a higher insulin dose, which might save them from DKA, and they are also they are more in need of something that might improve their weight. And actually, as of March 25 2019, dapagliflozin therapy is approved in Europe.

Click HERE and HERE to view press releases from the European Medicines Agency regarding its approval of new adjunct therapies for adults with type 1 diabetes.